<abstract xmlns="http://www.w3.org/1999/xhtml"> Olaparib is a potent oral inhibitor of PARP 1 &amp; 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer</abstract>

2nd Oncology Dpt, Cancer Hospital of Kifisia “Oi Agioi Anargiroi”

Oncology Dpt., Department of Clinical Therapeutics at “Alexandra” Hospital, Athens

Director, 2nd Oncology Dpt, Cancer Hospital of Kifisia “Oi Agioi Anargiroi”

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

<abstract xmlns="http://www.w3.org/1999/xhtml"> Background: Primary extranodal diffuse large B-Cell lymphoma (PE-DLBCL) accounts for about one-third of all cases of DLBCL. We reviewed the clinical and pathological characteristics of cases with PE-DLBCL presented to NCI, Egypt.Patients and methods: We retrospectively studied patients with pathologically documented PE-DLBCL presented to the National Cancer Institute between January 2008 and December 2010. Revision of histopathology and sub-classification of patients to germinal centre (GC) DLBCL and non-GC-DLBCL through immunostaining of CD10, BCL-6 and MUM-1 were done. Cases that were CD10+/BCL-6±/ MUM-1- were categorised as GC-DLBCL, while cases that were CD10-/BCL-6±/MUM-1+ were categorised as non-GC-DLBCL. Clinical data regarding baseline characteristics, chemotherapy given and the response to chemotherapy was collected.Results: A total of 57 patients of PE-DLBCL were included in the study. Mean age was 48.9 years (range 21-78), and 32 patients (56.1%) were females. Most frequent locations were gastrointestinal and liver (29.9% and 22.9 %; respectively). Forty-two patients (73.7%) were sub-classified as non-GC-DLBCL. The patients who were stage III/IV were more common (52.6%). Fifty-two patients received CHOP, 5 received CVP, and 6 patients received radiotherapy after finishing chemotherapy. Complete response rate (CR) was 64.9%, there was no difference in the CR (66.7%, 64.3%) and Overall Survival (53.3%, 52.4%) in GC-DLBCL group in comparison to non-GC-DLBCL group (p = 0.24 and 0.6; respectively). The CR and OS for patients with low international prognostic index (IPI) were significantly better than patients with intermediate or high IPI (p = 0.008 and 0.08, respectively).Conclusion: Non-GC-DLBCL is more common than GC-DLBCL in PE-DLBCL in Egyptian population. The most affected sites are gastrointestinal and liver reflecting the association between high frequency of hepatitis B and C and hepatic non-Hodgkin’s lymphoma (NHL). Stage of the disease and IPI remains the most important prognostic factor for PE-DLBCL.</abstract>

Medical Oncology Department, National Cancer Institute, Cairo University, Egypt

Pathology Department, National Cancer Institute, Cairo University, Egypt

Clinicopathologic Profile and Outcome of Extranodal Diffuse Large B-Cell NHL: Egyptian National Cancer Institute Experience

<abstract xmlns="http://www.w3.org/1999/xhtml"> INTRODUCTION: Sarcomas are a rare and heterogeneous group of tumours of mesenchymal origin. Single agent pazopanib showed activity in a phase II clinical trial designed to screen various soft tissue sarcoma subtypes [10] and a phase III [11] clinical trial followed resulting in FDA approval in 2012 for use in metastatic soft tissue sarcoma exposed to prior chemotherapy. METHODS: We conducted an independent computerised review of PubMed and ScienceDirect database up to May 2015 using combinations of terms such as soft tissue sarcoma, pazopanib, STS ,VEGFR2, TKIs ,angiogenesis, advanced sarcoma treatment, targeted therapy for sarcoma AIM: Our aim was to explore the role of pazopanib in soft tissue sarcoma (STS) treatment, its mode of action, the clinical trials supporting its approval, safety and efficacy, how the product fits into the real world and its contribution to the development of targeted therapy for STS CONCLUSION: Pazopanib is a valid, innovative and cost-effective approach in the treatment of advanced pre-treated STS</abstract>

Oncology Unit, Third Department of Medicine, University of Athens, Athens, Greece

Department of Medical Oncology, Ioannina University Hospital, Greece

The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature

<abstract xmlns="http://www.w3.org/1999/xhtml"> With the development of site-specific cancer therapy, identifying the primary origin allows the oncologist to personalise therapy for patients with the cancer of unknown primaries (CUPs). At present, immunohistochemistry (IHC) screening is the standard method used to postulate the primary site in CUP. In this retrospective study, we evaluated the prognostic benefit of identifying the primary site in CUP. All 84 patients who presented with suspected CUP to the Royal Stoke University Hospital between 2011 and 2012 were included in our study. Forty-eight percent (40/84) of these patients were unable to undergo necessary investigations to identify primary sites because of poor performance status. IHC screening was able to postulate the primary site in 59% (26/44) of the remaining patients with confirmed CUP. Therefore, the primary site was not identified in a significant proportion of patients with CUP. The median survival of confirmed CUP with probable primary site was 2.0 months (95% confidence interval (CI): 1.2 to 2.9 months), whereas the median survival of confirmed CUP with no probable primary site was 4.1 months (95% CI: 1.5 to 9.7 months). This difference in survival time was statistically significant. In addition, using the Cox regression model, we found that patients with confirmed CUP with primary sites had prognostically unfavourable diseases with a shorter median survival, regardless of the age of disease onset, gender, sites of metastases or number of metastases. One approach to improve the survival would be to start systemic therapy at the earliest possible opportunity rather than waiting for all investigation results, such as IHC.</abstract>

Evaluation of the prognostic benefit of identifying the probable primary site in cancer of unknown primary

AHEAD OF PRINT

Volume 14 (2023): Issue 1 (December 2023)

Volume 13 (2022): Issue 3 (December 2022)

Volume 13 (2022): Issue 2 (December 2022) 6TH HELLENIC CONGRESS OF ONCOLOGY

Volume 13 (2022): Issue 1 (December 2022)

Volume 12 (2021): Issue 3 (December 2021)

Volume 12 (2021): Issue 2 (December 2021) Supplementary Issue: 27th Hellenic Conference of Clinical Oncology

Volume 12 (2021): Issue 1 (May 2021)

Volume 11 (2020): Issue 3 (December 2020)

Volume 11 (2020): Issue 2 (July 2020)

Volume 11 (2020): Issue 1 (March 2020)

Volume 10 (2019): Issue 2 (December 2019)

Volume 10 (2019): Issue 1 (April 2019)

Volume 9 (2018): Issue 1 (December 2018)

Volume 8 (2017): Issue 1 (June 2017)

Volume 7 (2016): Issue 2 (June 2016)

Volume 7 (2016): Issue 1 (March 2016)

Volume 6 (2015): Issue 4 (December 2015)

Volume 6 (2015): Issue 3 (September 2015)

Volume 6 (2015): Issue 2 (June 2015)

Volume 6 (2015): Issue 1 (March 2015)

Volume 5 (2014): Issue 2 (December 2014)

Volume 5 (2014): Issue 1 (July 2014)

Forum of Clinical Oncology

 Why subscribe and read  We would like to present to you the Forum of Clinical Oncology (FCO), the official scientific journal of the Hellenic Society of Medical Oncology.In the Hellenic Society of Medical Oncology we want FCO to serve as a forum, for us all, to communicate clinical and research achievements in English; to share thoughts, opinions, facts, problems and solutions.We envision the journal to be the means, by which our efforts in the fight against cancer will become known to a wider audience, thus establishing our presence in the global setting. FCO publishes original and translational research articles relevant to diagnosis and treatment of cancer, state-of-the-art reviews, case reports, research articles, statements of opinion and comments, all related to clinical practice and basic research. A large number of eminent Greek and Foreign colleagues who participate in the National and International Editorial Boards, with their continuum direction and support, guarantee the high quality of the work published in FCO. In every issue published there will be something new, enjoyable and exciting to be read.  Why submit  We would like to welcome you to the Forum of Clinical Oncology (FCO), the official scientific journal of the Hellenic Society of Medical Oncology.In the Hellenic Society of Medical Oncology we share the view that there are many issues we deal with in our everyday clinical and research practice that are common to our colleagues geographically closer to us, in the Balkans and the Mediterranean basin, but also to those in other parts of the world. That led us to dare "the great leap forward": to broaden the scope of our Greek scientific journal for oncology, published in Greek for the last 10 years, and develop Forum of Clinical Oncology a web based open access journal in English.  FCO will serve as a forum for us all to communicate clinical and research achievements. One of the innovations of the journal is its online management from submission of an article to its publication. Online is more efficient: submitting, reviewing, proofreading, filing and indexing. However, the most important benefit of all is easy universal access.  English has become the common language amongst scientists from around the globe. This is the reason why we chose English as the official language of the journal. Many Greek colleagues have already published work in English in distinguished journals or have studied or worked abroad. We believe that the language change will not be an impediment for our Greek colleagues to present their work in FCO, whereas on the other hand it will allow our colleagues from other countries to participate.  The Forum of Clinical Oncology publishes original and translational research articles relevant to diagnosis and treatment of cancer, state-of-the-art reviews, case reports, research articles, statements of opinion and comments, all related to clinical practice and basic research.  We share the view that there should be no barriers to knowledge and thus, we decided Forum of Clinical Oncology to be an open-access journal, i.e., any work submitted to the journal and accepted for publication shall be made immediately available to the scientific community and the general public, via the journal's website and printed version. Authors are requested to adjust accordingly the information regarding their work they wish to make public. It is the desire of the editorial team to make this journal an interactive educational tool to acquire knowledge and it is addressed to scientists working with oncology.  Please join us in our effort and submit your work to the FCO.  Archiving  Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.  Plagiarism Policy  The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. 